No Data
Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)
Insider Buys Additional US$100k In Immunic Stock
Immunic Announces Publication of IMU-856 Data
Immunic Reports Positive Phase 1 Results for Celiac Disease Therapy Published in The Lancet | NASDAQ:IMUX
Express News | Immunic Announces Publication of Data From Phase 1/1B Clinical Trial of Imu-856 in the Peer Reviewed Journal, the Lancet Gastroenterology & Hepatology
Optimistic Buy Rating for Immunic Driven by Promising Trials and Market Opportunities for VidoCa
No Data
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
